In the early stages of gout, treatment can prevent pain and other complications from occurring. The condition typically affects the base of the big toe, and attacks tend to start in the morning or early afternoon. Symptoms generally worsen within 12 to 24 hours and may involve several joints. If left untreated, gout can spread to new joints. Often, the disease is diagnosed on the spot and can spread to other joints. The most common area affected by gout is the big toe, but it can strike any joint. Initially, the pain is most severe during the first four to 12 hours of an attack. After that, the pain can persist for days or weeks. Symptoms of gout often include swelling of the joint, itching, redness, and warmth. During an attack, range of motion may be limited. Medical professionals typically refer to flare-ups as “acute” and describe them as “unpredicted.”
Asia Gout Disease Treatment Marketโ Impact of Coronavirus (Covid-19) Pandemic
The Covid โ 19 pandemic is expected to drive growth of the Asia gout disease treatment market over the forecast period. Since December 2019, a novel coronavirus spread throughout China and across the world, causing a continuous increase in confirmed cases within a short period of time. The disease has spread to more than 100 countries across the globe and the World Health Organization declared it as a public health emergency. For instance, according to the World Health Organization Coronavirus Disease (COVID-19) Dashboard (WHO) report, the manifestation of the coronavirus disease (COVID-19) has resulted in more than 11 million infected individuals worldwide as of July 2020.
Furthermore, according to the CreakyJoints, May 2020, people with gout may be considered in a higher-risk group for potential COVID-19 complications. The coronavirus (COVID 19) pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors. The private healthcare sector is one the sectors, which has been majorly impacted by the COVID 19 pandemic.
๐๐๐ญ ๐ ๐ฎ๐ฅ๐ฅ ๐๐๐ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐จ๐ฉ๐ฒ ๐จ๐ ๐๐๐ฉ๐จ๐ซ๐ญ: (๐๐ง๐๐ฅ๐ฎ๐๐ข๐ง๐ ๐ ๐ฎ๐ฅ๐ฅ ๐๐๐, ๐๐ข๐ฌ๐ญ ๐จ๐ ๐๐๐๐ฅ๐๐ฌ & ๐ ๐ข๐ ๐ฎ๐ซ๐๐ฌ, ๐๐ก๐๐ซ๐ญ) @ https://www.coherentmarketinsights.com/insight/request-pdf/4141
The Asia gout disease treatment market is estimated to be valued atย US$ 643.55 Millionย in 2020 and is expected to exhibit aย CAGR of 9.1%ย during the forecast periodย (2020-2027).
Asia gout disease treatment market is witnessing significant growth owing to presence of major market players
Key players are more focused on adoption of inorganic growth strategies such as acquisitions, collaborations, and partnerships to strengthen their anti-gout drugs portfolio. For instance, in September 2019, Simcere Pharmaceutical Group and JW Pharmaceutical (both China-based companies) entered into a collaboration and exclusive license agreement for the development of anti-gout drug candidate URC-102 in China. Under this agreement, the responsibilities of clinical trial and registration will be taken by Simcere Pharmaceutical Group. The candidate, URC-102, is a selective inhibitor of uric acid transporter (URAT-1) and it is in Phase IIb clinical trial in patients with gout disease in South Korea.
Furthermore, big pharmaceutical companies such as Takeda Pharmaceutical and AstraZeneca adopted inorganic growth strategies. For instance, in April 2012, Takeda Pharmaceutical (Japan-based) acquired the URL Pharma Inc., a Philadelphia-based company, in order to expand itsย gout disease treatmentย portfolio with the acquisition of marketed gout therapy Colcrys (colchicine), developed by URL Pharma Inc.
Similarly, in December 2018, InventisBio announced that it had signed a collaboration agreement with Betta Pharma. Under this agreement, InventisBio will out-license D-0316’s rights in China (including mainland China, Hong Kong, and Taiwan) to Betta Pharma and to co-develop this drug in China. Betta Pharma will have the exclusive commercialization rights of D-0316 product in China.
๐๐จ ๐ ๐๐ญ ๐๐จ๐ซ๐ ๐๐ฎ๐ฌ๐ข๐ง๐๐ฌ๐ฌ ๐๐ญ๐ซ๐๐ญ๐๐ ๐ข๐๐ฌ ๐๐๐ช๐ฎ๐๐ฌ๐ญ ๐๐จ๐ซ ๐๐๐ฆ๐ฉ๐ฅ๐ @ https://www.coherentmarketinsights.com/insight/request-sample/4141
Asia Gout Disease Treatment Marketโ Restraints
The adverse effects and risks associated with drugs such as NSAIDS and urate-lowering agents is major factor hindering growth of this market. Most of the gout drugs are associated with some severe side effects, which may limit demand for these drugs. Nonsteroidal anti-inflammatory drugs (NSAIDs) may cause some gastric problems such as indigestion. In some cases, these drugs can cause gastric ulcers, bleeding, and rashes in gastrointestinal GI tract. Moreover, side effects such as intolerability and contraindication may limit the use of these drugs in the treatment of gout.
For instance, in February 2019, the U.S. Food and Drug Administration (FDA) announced to add a new boxed warning for febuxostat, as there is increased risk of death associated with Uloric (febuxostat) compared to another gout medicine, allopurinol. Febuxostat belongs to the urate-lowering agents.
Asia Gout Disease Treatment Marketโ Competitive Landscape
Some of the key players operating in the Asia gout disease treatment market include AstraZeneca Plc, Takeda Pharmaceutical Company Limited, Teijin Pharma Limited, Hikma Pharmaceuticals Plc., Hikma Pharmaceuticals Plc., Zyla Life Sciences, Horizon Therapeutics plc, JW Pharmaceutical CORPORATION, and LG Chem.
๐๐ฎ๐ซ๐๐ก๐๐ฌ๐ ๐๐ก๐ข๐ฌ ๐๐ซ๐๐ฆ๐ข๐ฎ๐ฆ ๐๐๐ฉ๐จ๐ซ๐ญ ๐๐ข๐ญ๐ก ๐ ๐ฅ๐๐ญ ๐๐๐ ๐๐๐๐ ๐๐ ๐ @ https://www.coherentmarketinsights.com/promo/buynow/4141
Table of Contents
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Route ofย Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Country
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Pipeline Analysis
- Regulatory Scenario
- Reimbursement Scenario
- Key Developments
- PEST Analysis
- Epidemiology
- Market Dynamics
- Covid โ 19 Impact Analysis
- Pre-COVID 19 Market Situation
- Post Covid – 19 Market Scenario
- Overall Impact on the Healthcare Industry
- Asia Gout Disease Treatment Market, By Drug Class, 2016 โ 2027, (US$ Million)
- Introduction
- Market Share Analysis, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 โ 2027
- Segment Trends
- Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 โ 2027, (US$ Million)
- Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 โ 2027, (US$ Million)
- Colchicine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 โ 2027, (US$ Million)
- Urate-lowering Agents
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 โ 2027, (US$ Million)
- Introduction
- Asia Gout Disease Treatment Market, Byย Route of Administration, 2016 โ 2027, (US$ Million)
- Introduction
- Market Share Analysis, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 โ 2027
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 โ 2027, (US$ Million)
- Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 โ 2027, (US$ Million)
- Introduction
- Asia Gout Disease Treatment Market, By Distribution Channel, 2016 โ 2027, (US$ Million)
- Introduction
- Market Share Analysis, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 โ 2027
- Segment Trends
- Hospital Pharmacies
- ย Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 โ 2027, (US$ Million)
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 โ 2027, (US$ Million)
- Online Pharmacies
- ย Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 โ 2027, (US$ Million)
- Introduction
View Press Release: https://www.coherentmarketinsights.com/press-release/asia-gout-disease-treatment-market-3408
About US:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact Us:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837